Amro Alsaid

Dr. Amro Alsaid

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
ACAlvaro E. Ulloa Cerna
Alvaro E. Ulloa Cerna
LJLinyuan Jing
Linyuan Jing
CGChristopher W. Good
Christopher W. Good
DVDavid P. Vanmaanen
David P. Vanmaanen
SRSushravya Raghunath
Sushravya Raghunath
BFBrandon K. Fornwalt
Brandon K. Fornwalt

1 June 2025 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Open access
GFGudrun Feuchtner
Gudrun Feuchtner
PLPietro G. Lacaita
Pietro G. Lacaita
JBJeroen Bax
Jeroen Bax
FRFatima Rodriguez
Fatima Rodriguez
RNRine Nakanishi
Rine Nakanishi
ARAlexander van Rosendael
Alexander van Rosendael
BACKGROUND: Coronary plaque features are imaging biomarkers of cardiovascular risk, but less is known about sex-specific patterns in their prognostic value. This study aimed to define sex differences in the coronary atherosclerotic phenotypes assessed by artificial intelligence–based quantitative computed tomography (AI-QCT) and the associated risk of major adverse cardiovascular events (MACEs). METHODS: Global multicenter registry including symptomatic patients with suspicion of coronary artery disease referred for coronary computed tomography angiography. AI-QCT analyzed 16 coronary artery disease features. The primary end point was MACE defined as death, myocardial infarction, late revascularization, cerebrovascular events, unstable angina, and congestive heart failure. RESULTS: Among 3551 patients (mean age, 59±12 years; 49.5% women), MACE occurred in 3.2% of women and 6.1% of men during an average follow-up of 4.8±2.2 years. The AI-QCT features total plaque volume, noncalcified plaque, calcified plaque, and percentage atheroma volume were significantly higher in men ( P <0.001), and high-risk plaques were more prevalent (9.2% versus 2.5%; P <0.0001). Independent of age and cardiovascular risk factors, the AI-QCT-derived features of total plaque volume, noncalcified plaque, calcified plaque, and percentage atheroma volume conferred a higher relative risk of MACE in women than men. For every 50-mm 3 increase in total plaque volume, relative risk increased by 17.7% (95% CI, 1.12–1.24) in women versus 5.3% (95% CI, 1.03–1.07) in men ( P interaction <0.001); for noncalcified plaque, relative risk increased by 27.1% (95% CI, 1.17–1.38) versus 11.6% (95% CI, 1.08–1.15; P interaction =0.0015); and for calcified plaque, relative risk increased by 22.9% (95% CI, 1.14–1.33) versus 5.4% (95% CI, 1.01–1.10; P interaction =0.0012), respectively. Similarly, for percentage atheroma volume, the risk was higher in women. The findings remained unchanged when restricted to a secondary composite end point (death and myocardial infarction). CONCLUSIONS: The AI-QCT plaque features, total plaque volume, noncalcified plaque, calcified plaque, and percentage atheroma volume, conferred a higher relative MACE risk in women and may prompt more aggressive antiatherosclerotic therapy and reinforced preventive interventions. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04279496.

1 August 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
ECEric D. Carruth
Eric D. Carruth
MQMaria Qureshi
Maria Qureshi
AAAmro Alsaid
Amro Alsaid
MKMelissa A. Kelly
Melissa A. Kelly
HCHugh Calkins
Hugh Calkins
CHChristopher M. Haggerty
Christopher M. Haggerty
Background: The FLNC gene has recently garnered attention as a likely cause of arrhythmogenic cardiomyopathy, which is considered an actionable genetic condition. However, the association with disease in an unselected clinical population is unknown. We hypothesized that individuals with loss-of-function variants in FLNC ( FLNC LOF ) would have increased odds for arrhythmogenic cardiomyopathy-associated phenotypes versus variant-negative controls in the Geisinger MyCode cohort. Methods: We identified rare, putative FLNC LOF among 171 948 individuals with exome sequencing linked to health records. Associations with arrhythmogenic cardiomyopathy phenotypes from available diagnoses and cardiac evaluations were investigated. Results: Sixty individuals (0.03%; median age 58 years [47–70 interquartile range], 43% male) harbored 27 unique FLNC LOF . These individuals had significantly increased odds ratios for dilated cardiomyopathy (odds ratio, 4.9 [95% CI, 2.6–7.6]; P <0.001), supraventricular tachycardia (odds ratio, 3.2 [95% CI, 1.1–5.6]; P =0.048), and left-dominant arrhythmogenic cardiomyopathy (odds ratio, 4.2 [95% CI, 1.4–7.9]; P =0.03). Echocardiography revealed reduced left ventricular ejection fraction (52±13% versus 57±9%; P =0.001) associated with FLNC LOF . Overall, at least 9% of FLNC LOF patients demonstrated evidence of penetrant disease. Conclusions: FLNC LOF variants are associated with increased odds of ventricular arrhythmia and dysfunction in an unselected clinical population. These findings support genomic screening of FLNC for actionable secondary findings.

1 April 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
ECEric D. Carruth
Eric D. Carruth
DBDominik Beer
Dominik Beer
AAAmro Alsaid
Amro Alsaid
MSMarci L.B. Schwartz
Marci L.B. Schwartz
MMMegan McMinn
Megan McMinn
CHChristopher M. Haggerty
Christopher M. Haggerty
Background: Genomic screening holds great promise for presymptomatic identification of hidden disease, and prevention of dramatic events, including sudden cardiac death associated with arrhythmogenic cardiomyopathy (ACM). Herein, we present findings from clinical follow-up of carriers of ACM-associated pathogenic/likely pathogenic desmosome variants ascertained through genomic screening. Methods: Of 64 548 eligible participants in Geisinger MyCode Genomic Screening and Counseling program (2015–present), 92 individuals (0.14%) identified with pathogenic/likely pathogenic desmosome variants by clinical laboratory testing were referred for evaluation. We reviewed preresult medical history, patient-reported family history, and diagnostic testing results to assess both arrhythmogenic right ventricular cardiomyopathy and left-dominant ACM. Results: One carrier had a prior diagnosis of dilated cardiomyopathy with arrhythmia; no other related diagnoses or diagnostic family history criteria were reported. Fifty-nine carriers (64%) had diagnostic testing in follow-up. Excluding the variant, 21/59 carriers satisfied at least one arrhythmogenic right ventricular cardiomyopathy task force criterion, 11 (52%) of whom harbored DSP variants, but only 5 exhibited multiple criteria. Six (10%) carriers demonstrated evidence of left-dominant ACM, including high rates of atypical late gadolinium enhancement by magnetic resonance imaging and nonsustained ventricular tachycardia. Two individuals received new cardiomyopathy diagnoses and received defibrillators for primary prevention. Conclusions: Genomic screening for pathogenic/likely pathogenic variants in desmosome genes can uncover both left- and right-dominant ACM. Findings of overt cardiomyopathy were limited but were most common in DSP -variant carriers and notably absent in PKP2 -variant carriers. Consideration of the pathogenic/likely pathogenic variant as a major criterion for diagnosis is inappropriate in the setting of genomic screening.

1 December 2025 in JACC: Cardiovascular Imaging
Verified
Journal Article
Open access
ARAlexander van Rosendael
Alexander van Rosendael
RNRine Nakanishi
Rine Nakanishi
JBJeroen J. Bax
Jeroen J. Bax
GPGianluca Pontone
Gianluca Pontone
SMSaima Mushtaq
Saima Mushtaq
IDIbrahim Danad
Ibrahim Danad
The severity and extent of whole heart coronary plaque volume and stenosis can be reliably measured by artificial intelligence-guided quantitative coronary computed tomography angiography (AI-QCT). Limited data are available on the potential incremental prognostic value compared with currently recommended qualitative coronary computed tomography angiography (CTA) reads and the coronary artery calcium score (CACS). The aim of this study was to evaluate the prognostic value of AI-QCT compared with human coronary CTA reads, including the CAD-RADS (Coronary Artery Disease-Reporting and Data System), CACS, and the modified Duke Index. CONFIRM2 (Quantitative COroNary CT Angiography Evaluation For Evaluation of Clinical Outcomes: An InteRnational, Multicenter Registry) is a multicenter, international, observational cohort study of patients undergoing clinically indicated coronary CTA with follow-up for major adverse cardiac events (MACE). Asymptomatic patients and those with cardiac history were excluded. Coronary artery disease presence, extent, and composition were quantified by AI-QCT across the coronary tree, yielding 24 patient-, vessel-, and plaque-level variables. On the basis of prior analyses, noncalcified plaque burden and diameter stenosis were identified as the strongest predictors and combined for statistical modeling as "AI-QCT." Comparator computed tomography scores included CAD-RADS, CACS, and the modified Duke Index, whereas clinical predictors were summarized in the risk factor-weighted clinical likelihood score. Area under the curve (AUC) and continuous net reclassification index (NRI) were calculated to assess the incremental value. The primary endpoint was MACE (death, myocardial infarction [MI], stroke, heart failure, late revascularization, or hospital stay for unstable angina), and the secondary endpoint was death or MI. In 1,916 patients with all risk scores available, 87 (4.5%) MACE and 27 (1.4%) death/MI events occurred during 3 years of follow-up. There was a stepwise risk increase with higher coronary artery disease classifications with CAD-RADS and CACS. The addition of AI-QCT significantly improved risk stratification for MACE compared with CAD-RADS (AUC: 0.81 vs 0.79; P < 0.001 and NRI: 0.47; P < 0.001), CACS (AUC: 0.79 vs 0.70; P < 0.001 and NRI 0.61; P < 0.001), the modified Duke Index (AUC: 0.81 vs 0.76; P < 0.001 and NRI: 0.52; P < 0.001), and CAD-RADS + CACS model (AUC: 0.81 vs 0.79; P = 0.004 and NRI: 0.54; P < 0.001). AI-QCT also improved discrimination when results were adjusted for the risk factor-weighted clinical likelihood and for the prediction of death/MI. Excluding 195 patients with severe stenosis (≥70%), in a multivariable model of CAD-RADS and AI-QCT, only AI-QCT was significantly associated with MACE and death/MI, and AI-QCT significantly improved risk stratification compared with CAD-RADS for MACE (AUC: 0.77 vs 0.72; P < 0.001 and NRI: 0.54; P < 0.001) and death/MI (AUC: 0.81 vs 0.73; P = 0.011 and NRI: 0.69; P = 0.001). AI-QCT provided incremental prognostic information compared with CAD-RADS 2.0, CACS, and the modified Duke Index for the prediction of MACE as well as the secondary endpoint of death or nonfatal MI.

28 April 2016 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
AAAmro Alsaid
Amro Alsaid
PCPeter J. Cawley
Peter J. Cawley
TBTerry D. Bauch
Terry D. Bauch
CGChristopher W. Good
Christopher W. Good
Accessory left atrial cords are a rare but clinically important finding. If not diagnosed, or left untreated, it can result in severe mitral regurgitation, valvular cardiomyopathy, atrial fibrillation, or interfere with catheter manipulation during ablation. We present a case where the diagnosis of accessory cord was made using three-dimensional transoesophageal echocardiography (3D-TEE) in a patient presenting with non-ischaemic decompensated heart failure secondary to valvular cardiomyopathy.